Su J, et al. - In Chinese postmenopausal women with untreated characterized KRAS exon 2 wild-type metastatic colorectal cancer (MCC), researchers assessed the effectiveness and safety of capecitabine (CAP) plus bevacizumab (CAP-B) vs CAP in maintenance treatment following 6-cycle capecitabine, oxaliplatin, and bevacizumab (CAPOXB) induction therapy. For this investigation, prospectively maintained databases from 2012 to 2016 were reviewed to assess cohorts with untreated characterized KRAS exon 2 wild-type MCC and stable disease or better following 6-cycle CAPOXB induction treatment. Study participants included 263 women with untreated characterized KRAS exon 2 wild-type MCC and stable disease or better following 6-cycle CAPOXB induction treatment. In these patients, CAP- B maintenance after 6-cycle CAPOX- B treatment is poorly tolerated and has modest (if any) benefit vs CAP maintenance. Investigators found that the CAP-B-treated cohort had significantly more grade 3 or 4 diarrhea vs the CAP-treated cohort.